MAX
Company Analysis Protagenic Therapeutics, Inc.
1. Summary
Advantages
- Price (0.4 $) is less than fair price (2.84 $)
- Current debt level 17.59% is below 100% and has decreased over 5 years from 156.25%.
Disadvantages
- Dividends (0%) are below the sector average (0.51%).
- The stock's return over the last year (-89.61%) is lower than the sector average (17.85%).
- The company's current efficiency (ROE=-236.05%) is lower than the sector average (ROE=-92.73%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Protagenic Therapeutics, Inc. | Technology | Index | |
|---|---|---|---|
| 7 days | -15.3% | -20.2% | -3% |
| 90 days | -75.8% | 4.4% | -0.3% |
| 1 year | -89.6% | 17.8% | 12.4% |
PTIX vs Sector: Protagenic Therapeutics, Inc. has significantly underperformed the "Technology" sector by -107.46% over the past year.
PTIX vs Market: Protagenic Therapeutics, Inc. has significantly underperformed the market by -101.97% over the past year.
Slightly volatile price: PTIX is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: PTIX with weekly volatility of -1.72% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.4 $) is lower than the fair price (2.84 $).
Price significantly below the fair price: The current price (0.4 $) is 610% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-2.44) is higher than that of the sector as a whole (-143).
P/E vs Market: The company's P/E (-2.44) is higher than that of the market as a whole (-107.89).
5.3. P/BV
P/BV vs Sector: The company's P/BV (33.18) is higher than that of the sector as a whole (10.37).
P/BV vs Market: The company's P/BV (33.18) is lower than that of the market as a whole (72.83).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (16.33).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (116.06).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-5.8) is lower than that of the sector as a whole (83.77).
EV/Ebitda vs Market: The company's EV/Ebitda (-5.8) is higher than that of the market as a whole (-81.5).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 2.1% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (2.1%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-19.39%).
6.4. ROE
ROE vs Sector: The company's ROE (-236.05%) is lower than that of the sector as a whole (-92.73%).
ROE vs Market: The company's ROE (-236.05%) is lower than that of the market as a whole (-6.44%).
6.6. ROA
ROA vs Sector: The company's ROA (-175.98%) is lower than that of the sector as a whole (112.4%).
ROA vs Market: The company's ROA (-175.98%) is lower than that of the market as a whole (38.41%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-100.07%) is lower than that of the sector as a whole (8.62%).
ROIC vs Market: The company's ROIC (-100.07%) is lower than that of the market as a whole (9.36%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.51%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
